The QualityStocks Daily Tuesday, November 16th, 2021

Today's Top 3 Investment Newsletters

QualityStocks(GWHP) $0.2450 +63.33%

MarketClub Analysis(PROG) $4.8400 +39.48%

Trades Of The Day(TCDA) $7.9700 +25.51%

The QualityStocks Daily Stock List

BIMI International Medical (BIMI)

StockMarketWatch, QualityStocks, MarketClub Analysis, TradersPro, StreetInsider, Real Pennies, TradersPro Morning, TopPennyStockMovers, TheMicrocapNews,, OilAndEnergyInvestor and InvestorsUnderground reported earlier on BIMI International Medical (BIMI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BIMI International Medical Inc. (NASDAQ: BIMI) (FRA: 63N) is a company engaged in the wholesale and retail distribution of pharmaceutical products, medical devices and other healthcare products.

The firm has its headquarters in Chongqing, the People’s Republic of China and was incorporated in 2000, on October 31st. Prior to its name change in June 2021, the firm was known as Boqi International Medical Inc. The firm serves consumers in China.

The company is locally focused and community-based, engaging its consumers with seamless, simple, accessible and more affordable care when and where they need it. It hopes to establish a chain of hospitals specializing in gynecology and obstetrics in the future.

The enterprise provides an extensive range of consumer-directed health products and related services, which include health information technology services and products, chronic disease management services, behavioral, pharmacy and medical health plans. It also provides over-the-counter and prescription drugs, health foods, nutritional supplements and sundry products, as well as personal and family care products, traditional Chinese medicines and miscellaneous items. It offers these products under the Lijiantang Pharmacy brand. In addition to this, the enterprise offers research and development services. It sells medications and other healthcare products to consumers directly through its directly owned stores.

The company is set to acquire Zhuoda Pharmaceutical Co. Ltd, which supplies pharmaceuticals and medical equipment on wholesale basis. This move will allow the company to expand its product coverage as well as generate shareholder value, which will have a positive effect on the company’s investments, as well as on its growth.

BIMI International Medical (BIMI), closed Tuesday's trading session at $1, up 53.1394%, on 129,962,311 volume with 153,810 trades. The average volume for the last 3 months is 129.962M and the stock's 52-week low/high is $0.53/$2.81.

Global WholeHealth Partners Corporation (GWHP)

PennyStockProphet, Profitable Trader Authority, PennyStockScholar, Penny Pick Finders, OTCtipReporter, Buzz Stocks, StockOnion, HotOTC, QualityStocks and HotMicrocap Stocks reported earlier on Global WholeHealth Partners Corporation (GWHP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Global WholeHealth Partners Corporation manufactures and markets different in vitro diagnostic test kits in the USA. It offers rapid diagnostic tests. These include the CoVid-19 test, the whole blood Ebola test, the whole blood Zika test, the whole blood rapid TB test, and diverse other tests for Over-The-Counter (OTC) or consumer-use, and point-of-care, which includes hospitals, physicians' offices, and medical clinics. Global WholeHealth Partners lists on the OTC Markets. The Company has its head office in San Clemente, California.

Global WholeHealth has a track record of pioneering two types of Invitro Diagnostic Point-of-Care tests. One is the Rapid Diagnostic Test (RDT). The other is the Real-time PCR Test. The Company’s emphasis is encompassing, improving, and preserving the quality of life through providing quick, adequate, and accurate test results to prompt early treatment and cut cost of accumulated diseases worldwide.

Global WholeHealth provides innovative technology utilizing In-vitro Diagnostic (IVD) Real-Time PCR Machines that detect between 1 1⁄2 hours, and Rapid Diagnostic Testing (RDT) Serum Plasma that detect between 15 -20 minutes, which the Company states predict diseases ahead of its industry competitors. Global WholeHealth can identify a new virus and create a specific test within 8 -12 weeks. The Company states that it can do so for a fraction of the cost of its competitors.

Global WholeHealth Partners is the only company with the Rapid Diagnostic Kits to test for Ebola and Zika. The Rapid Diagnostic Kits do not have to be refrigerated. In addition, they last up to 18 months.

Previously, Global WholeHealth Partners announced it now offers the new Food and Drug Administration (FDA) cleared Fingerstick for Rapid COVID-19 test results in minutes. The Company recognizes that there is a critical need for quicker testing and faster results when it comes to fighting COVID. With the new fingerstick test, healthcare providers can prick a patient’s finger and get results in minutes without having to wait for venous blood.

Global WholeHealth Partners Corporation (GWHP), closed Tuesday's trading session at $0.245, up 63.3333%, on 2,169,121 volume with 435 trades. The average volume for the last 3 months is 2.169M and the stock's 52-week low/high is $0.13/$3.30.

Atacama Resources International, Inc. (ACRL)

QualityStocks, Wolf of Penny Stocks, Epic Stock Picks, ProTrader, PHUB News, Penny Stock Titans, Penny Picks, Monster Alerts, MicroCapDaily, MegaPennyStocks, MarketBeat, DSR News and Damn Good Penny Picks reported earlier on Atacama Resources International, Inc. (ACRL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Atacama Resources International, Inc. has significant mining claims in the greater Kirkland Lake area of Northern Ontario. Metals and minerals under potential exploration include gold, silver, diamonds, graphite and cobalt. Furthermore, major deposits of copper and iron ore are included in the mining claims. Atacama Resources International is headquartered in Plantation, Florida.  

Regarding Minerals, the Company has numerous claims on 4460 acres in the Kirkland Lake and other areas of mineral-rich northern Ontario. The Company’s initial line of business is a combination of mining, acquisition, as well as development of mining interests in the Kirkland Lake region.

Atacama Resources International announced last September that it engaged Canadian Exploration Services Ltd. (CXS) to conduct a geological evaluation of the Company’s Cabo property. The Cabo property comprises Mining Claim 4225513, located in the Township of Lorrain in the heart of all the high-profile cobalt activity surrounding the historic mining town of Cobalt, Ontario.

Atacama Resources has acquired the mineral rights for the Mystery Graphite Property that comprises 1740 acres situated roughly 60 miles south of Timmins, Ontario. The acquisition of the mineral rights includes receiving core samples collected from numerous diamond drill sites earlier conducted on the property.

Additionally, Atacama Resources is involved in a new line of business that it states will make the highways of the U.S. and Canada safer and saves lives in the process. The Company, as part of its expansion portfolio, acquired Good2Drive™, Inc. Good2Drive, Inc. is a wholly-owned subsidiary of Atacama Resources International.   

Good2Drive™ is an entity that has the rights to an application (app), which detects levels of cognitive awareness and reports those levels in accordance with the users' demands and needs. The Company’s technology business includes the innovative Smartphone application Good2Drive and also follow on products that will be released this year.   

Atacama Resources International released Good2Drive in 2017. Good2Drive is a mobile application that enables drivers, corporate fleets, and law enforcement to test a driver's cognitive alertness before getting behind the wheel of a motor vehicle. Good2Drive uses a 60-90 second image matching test using a patented algorithm that was created based on the scientific study of cognitive abilities at different West Coast hospitals and universities. 

Good2Drive’s dedication is to providing Smartphone hosted applications founded on its proprietary testing for cognitive awareness. Its set of Smartphone hosted apps will include cognitive tests for care givers, seniors with impairments, remote employees in potentially hazardous environments, and other situations where it is necessary to be cognitively alert.

Atacama Resources International also has its Good2Drive/Fleet. This is a mobile application. It enables commercial fleet owners and operators to manage manifold drivers as they test their mental alertness before getting behind the wheel of a vehicle.

Atacama Resources International, Inc. (ACRL), closed Tuesday's trading session at $0.0198, up 33.7838%, on 2,519,534 volume with 69 trades. The average volume for the last 3 months is 2.52M and the stock's 52-week low/high is $0.005/$0.05.

Progenity (PROG)

MarketClub Analysis, Schaeffer's, QualityStocks, StreetInsider, MarketBeat, TradersPro, Daily Trade Alert, Trades Of The Day and InvestorPlace reported earlier on Progenity (PROG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Progenity Inc. (NASDAQ: PROG) (FRA: 4ZU) is a biotechnology firm that is engaged in the development and commercialization of specialized diagnostic and molecular testing products to clinicians in the U.S.

The firm has its headquarters in San Diego, California and was incorporated 2010 by Harry Stylli and Paul W. Hawran. Prior to its name change in November 2013, the firm was known as Ascendant MDX Inc. It serves consumers in the U.S. and operates as part of the health care sector, in the medical and diagnostic equipment and devices sub-industry.

The company offers in vitro molecular tests that have been developed to improve lives by providing information that is used to guide physicians and patients when making medical decisions during important life stages.

Its products include a hereditary cancer screening test that looks for genes linked to inherited risk of cancers like pancreatic, colorectal, ovarian and breast cancer known as Riscover; a test that screens for carrier status of hereditary ailments in early pregnancy known as Preparent and a non-invasive prenatal screening test that is provided to women in early pregnancy that screens for chromosome abnormalities like trisomy 13, 18 and down syndrome known as Innatal. In addition to this, it also offers a preeclampsia rule-out test called Preecludia and a non-invasive test for individuals at risk for rare single gene disorders known as Resura. Furthermore, the enterprise is engaged in the development of therapies for gastro-intestinal-related disorders, like PGN-OB2, PGN-600 and PGN-001.

The company recently launched its strategic transformation into becoming a biotech firm, which will focus on its R&D pipeline. This move will position the business better for future growth while also helping transform and address significant markets by enhancing patient outcomes, which will in turn attract investments into the company.

Progenity (PROG), closed Tuesday's trading session at $4.84, up 39.4813%, on 353,515,135 volume with 827,400 trades. The average volume for the last 3 months is 335.617M and the stock's 52-week low/high is $0.657/$7.86.

Sunshine Biopharma (SBFM)

QualityStocks, Investor Ideas, PennyStocks24, Ceocast News, Stock Twiter, OTCPicks, Gorilla Stock Trades, Pennybuster, Jet-Life Penny Stocks, AllPennyStocks, Fast Money Alerts, FeedBlitz, Greenbackers, Investor Stock Alerts, Ironman Stock, MassiveStockProfits, 007 Stock Chat, Otcstockexchange, Winston Small Cap, Penny Stock General, PennyStockSpy, Shiznit Stocks, Stock Roach, Stock Shock and Awe, StockHideout, Whisper from Wall Street and Mina Mar Marketing Group reported earlier on Sunshine Biopharma (SBFM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sunshine Biopharma Inc. (OTC: SBFM) is a pharmaceutical firm that is engaged in researching, developing and commercializing therapies for different forms of cancer.

The firm has its headquarters in Pointe-Claire, Canada and was incorporated in 2006, on August 31st. It is part of the drug wholesaler’s industry and operates in the healthcare sector under the biotech and pharma sub-industry.

The company is party to a license agreement with the University of Georgia to further advance developing a pair of anti-Covid-19 compounds in parallel with SBFM-PL4, its anti-Covid-19 lead compound. Its goal is to become a fully integrated pharmaceutical firm that offers proprietary and generic drugs for treating cancer and other chronic and acute indications. Its products include Essential 9, SBI-Finasteride, SBI-Bicalutamide, SBI-Letrozole, SBI-Anastrozol and Adva-27a.

Its product pipeline includes an anti-coronavirus treatment compound dubbed SBFM-PL4; a dietary supplement tablet named Essential 9 and a GEM-difluorinated C-glycoside derivative of podophyllotixin dubbed Adva-27a which is indicated for the treatment of liver, ovarian, colon, bladder, prostate, brain, lung, testicular, lymphoma, leukemia and other cancer types, as well as eliminating multidrug resistant cancer cells, including uterine sarcoma cells, small-cell lung cancer, breast cancer and pancreatic cancer. In addition to this, it also offers generic prescription drugs for treating benign prostatic hyperplasia, prostate cancer and breast cancer.

The American Cancer Society approximates that over a million individuals are diagnosed each year with cancer in the U.S., noting that more than 11 million Americans are currently living with cancer. The company may soon introduce a new cancer treatment into the market, which will be beneficial to patients suffering from these ailments as well as company stakeholders.

Sunshine Biopharma (SBFM), closed Tuesday's trading session at $0.0803, up 37.5%, on 7,849,693 volume with 391 trades. The average volume for the last 3 months is 7.85M and the stock's 52-week low/high is $0.0106/$0.314.


We reported earlier on PCT (PCTL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PCT Ltd. (OTC: PCTL) is a technology licensing firm that is engaged in designing, developing, manufacturing and licensing environmentally safe solutions for worldwide sustainability across the globe.

The company, which operates through its subsidiary Paradigm Convergence Technologies Corporation, is based in Little River, South Carolina. Prior to its name change in February 2018, the company, which was incorporated on February 27, 1986 was known as Bingham Canyon Corporation.

It markets new technologies and products for the oil and gas, agriculture and healthcare industries. The firm’s products include the Survivalyte system, small volume systems, large volume systems, the Annihilyzer system and many more.

The enterprise provides a surfactant, degreaser and mild detergent called Catholyte that’s utilized for janitorial cleaning purposes. In addition to this, it also provides a disinfectant/sanitizer microbiocide known as Hydrolyte, which is used to sanitize and disinfect water in industrial waste-water systems as well as in private and public water systems; in the gas and oil industry to eliminate sulfate reducing bacteria and gas and oil wells; to disinfect water in the agriculture industry for various applications in animal husbandry, post and pre-harvest crop disinfection and sanitize food processing as well as in institutional facilities, like schools, correctional facilities, hotels, nursing homes and hospitals.

The company, which not only increased their revenue in 2020 but also expanded their business model, is now focusing on supporting their distributors and executing procedures and policies that will significantly grow the company’s capture market and topline share. This will be beneficial both to the firm’s investors as well as its upward trajectory.

PCT (PCTL), closed Tuesday's trading session at $0.0168, up 27.2727%, on 29,746,189 volume with 605 trades. The average volume for the last 3 months is 29.746M and the stock's 52-week low/high is $0.0075/$0.03425.

Avrobio Inc. (AVRO)

MarketBeat, StreetInsider, StockMarketWatch, QualityStocks, BUYINS.NET, The Online Investor and InvestorPlace reported earlier on Avrobio Inc. (AVRO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Avrobio Inc. (NASDAQ: AVRO) is a clinical-stage gene therapy firm which is focused on the development of ex vivo lentiviral-based gene therapies for the treatment of rare ailments.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2015 by Jeffrey Medin, Christopher Mason, Kim Warren and Geoff Mackay. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers across the globe.

The company is focused on accelerating scientific breakthroughs associated with the convergence of gene and cell therapies. It believes that gene therapy possesses the potential to deliver disease modifying effects and possibly, life-long cures from a sole infusion of genetically-modified cells. This is done by modifying a patient’s cells to deliver new genes to cure severe debilitating ailments.

The enterprise’s product pipeline comprises of a gene therapy dubbed AVR-RD-01, which is undergoing phase 1 and 2 clinical trials evaluating its effectiveness in treating Fabry disease; and AVR-RD-02, which is in a phase 2 clinical trial and has been developed to treat type 1 Gaucher disease. It also develops AVR-RD-06, for the treatment of type 3 Gaucher disease; AVR-RD-05, to treat Hunter syndrome; and AVR-RD-04, which is in phase 2 clinical trial testing its efficacy in treating cystinosis. The enterprise also develops AVR-RD-03, which is in preclinical development for the treatment of Pompe disease.

The company recently reported their latest clinical results at the 2021 European Society of Cell and Gene Therapy virtual congress, with its CEO noting that the safety data of its formulations coupled with the durability and effectiveness data supported the potential of its gene therapies and their ability to transform the lives of patients living with rare disorders.

Avrobio Inc. (AVRO), closed Tuesday's trading session at $5.09, off by 1.5474%, on 287,631 volume with 3,615 trades. The average volume for the last 3 months is 284,619 and the stock's 52-week low/high is $5.06/$20.07.

AC Immune SA (ACIU)

MarketBeat, StockMarketWatch, TraderPower, StreetInsider, Schaeffer's, MarketClub Analysis, BUYINS.NET, TradersPro, The Street, QualityStocks and reported earlier on AC Immune SA (ACIU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

AC Immune SA (NASDAQ: ACIU) (FRA: IMR) is a clinical stage biopharmaceutical firm that is focused on the discovery and development of medications and diagnostic products for preventing and treating neurodegenerative ailments linked to protein misfolding.

The firm has its headquarters in Lausanne, Switzerland and was incorporated in 2003, on February 13th by Alexey V. Eleesiv, Andrea Pfeifer, Ruth Greferath, Fred van Leuven, Roscoe Brady, Claude Nicolau and Jean-Marie Lehn. It operates as part of the scientific research and development services industry, under the healthcare sector. The firm serves consumers around the globe.

The company has designed 2 platforms, i.e. the Morphomer and SupraAntigen platforms, which can generate small molecules, antibodies and vaccines that can selectively interact with misfolded proteins. It is party to collaboration and license agreements with WuXi Biologics; Eli Lilly and Company; Life Molecular Imaging SA; Essex Bio-Technology; Nestle Institute of Health Sciences; Janssen Pharmaceuticals Inc.; Biogen International GmbH; and Genentech Inc.

The enterprise’s pipeline is made up of an anti-A-beta vaccine candidate dubbed ACI-24, which has completed a phase 1b trial for Down syndrome and is undergoing a phase 2 clinical study for Alzheimer’s disease. It is also developing an anti-Tau vaccine known as ACI-35, which has completed a phase 1b study; and a conformation-specific monoclonal antibody known as Crenezumab, which is undergoing a phase 2 clinical prevention trial for Alzheimer’s.

The company is focused on its expansion strategy, having recently acquired PD01 from Affiris’. This acquisition has added a clinically validated candidate in Parkinson’s disease and strengthened its active vaccines portfolio. Its objective remains to develop new therapeutics for degenerative ailments.

AC Immune SA (ACIU), closed Tuesday's trading session at $5.75, off by 0.519031%, on 442,811 volume with 2,650 trades. The average volume for the last 3 months is 434,672 and the stock's 52-week low/high is $4.81/$12.61.

Biofrontera AG (BFRA)

MarketBeat and StockMarketWatch reported earlier on Biofrontera AG (BFRA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Biofrontera AG (NASDAQ: BFRA) is a biopharmaceutical firm that is focused on developing and commercializing pharmaceutical products for treating dermatological ailments and conditions that are mainly caused by exposure to sunlight, which in turn causes sun damage to the skin.

The firm has its headquarters in Leverkusen, Germany and was incorporated in 1997 by Hermann Lübbert. It operates as part of the scientific research and development services industry and has seven companies in its corporate family. The firm serves consumers around the globe, with a focus on the United States, Israel and Europe.

The company operates five wholly owned subsidiaries, which include Biofrontera Inc. in the U.S. It is party to a partnership and collaboration agreement with Maruho Co. Ltd.

The enterprise distributes dermatological drugs and medical cosmetics for treating, protecting and caring for the skin. Its product portfolio comprises of a generic drug known as Aktipal for acne treatment; a prescription antibiotic cream dubbed Xepi, for the treatment of impetigo; and a prescription drug dubbed Ameluz, which has been developed to treat field-directed and lesion-directed actinic keratosis. Ameluz is also indicated for the treatment of nodular basal cell carcinoma and field cancerization. In addition to this, the enterprise develops an OTC line of skin care cosmetic products dubbed Belixos; and a photodynamic therapy known as the BF-RhodoLED lamp, which is indicated for field-directed and lesion-directed treatment of actinic keratosis.

The firm recently received approval for its BF-RhodoLED lamp from the FDA, to be used in combination with its Ameluz formulation for the treatment of moderate and mild actinic keratosis on the scalp and face. This approval will have a positive influence on investments into the firm as well as boost the firm’s growth.

Biofrontera AG (BFRA), closed Tuesday's trading session at $4.475, off by 1.6484%, on 12,651 volume with 211 trades. The average volume for the last 3 months is 12,651 and the stock's 52-week low/high is $4.13/$9.87.

Appili Therapeutics (APLIF)

BUYINS.NET reported earlier on Appili Therapeutics (APLIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Appili Therapeutics Inc. (OTCQX: APLIF) (TSE: APLI) is a biopharmaceutical firm that is engaged in the acquisition and development of new medications for unmet needs of infectious illnesses.

The firm has its headquarters in Halifax, Canada and was incorporated in 2015, on May 7th. It serves consumers in Canada.

The company’s aim is to build and advance an adverse portfolio of anti-infective programs. Its approach is focused on matching clearly defined medical needs with the opportunity for more effective solutions which range from improvements in current therapies to an entirely new class of anti-infectives. The company is party to a strategic alliance with AiPharma Global Holdings LLC, which entails the development of its Favipiravir formulation.

The enterprise’s portfolio comprises of its ATI-1701 candidate, which is a live-attenuated vaccine for Francisellatularensis; an oral suspension formulation of the metronidazole antibiotic dubbed ATI-1501, which is indicated for patients who have difficulty swallowing; and a drug discovery program dubbed ATI-1503, which develops a class of gram-negative targeting antibiotics. It also develops a clinical-stage antifungal candidate dubbed ATI-2307, which is in its clinical stage and is indicated for the treatment of invasive candidiasis and cryptococcal meningitis. In addition to this, the enterprise is engaged in the development of its Favipiravir candidate (Avigan/Reeqonus), for the treatment of the coronavirus and pandemic influenza.

The firm recently announced its financial results for the second quarter of its 2021 fiscal year, with its CEO noting that they achieved key development milestones, including the expansion of its drug development infrastructure, which will allow the firm to tackle infectious disease threats and advance its anti-infective pipeline.

Appili Therapeutics (APLIF), closed Tuesday's trading session at $0.172, off by 4.6034%, on 329,958 volume with 66 trades. The average volume for the last 3 months is 329,958 and the stock's 52-week low/high is $0.1241/$1.30.

Organicell Regenerative Medicine (OCEL)

PennyPickAlerts reported earlier on Organicell Regenerative Medicine (OCEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Organicell Regenerative Medicine Inc. (OTCQB: OCEL) is a clinical-stage biopharmaceutical firm that is focused on developing biological therapeutics to treat degenerative ailments.

The firm has its headquarters in Miami, Florida and was incorporated in 2011, on August 9th by Maria Ines Mitrani, Albert Mitrani and John Goodhew. Prior to its name change in June 2018, the firm was known as Biotech Products Services and Research Inc. It operates as part of the scientific research and development services industry, under the healthcare sector. The firm has eight companies in its corporate family and serves consumers around the globe.

The company is party to an agreement with Oklahoma State University, which entails the assessment of its Zofin formulation as an effective treatment for respiratory ailments caused by viral infections. It is also party to a research and development agreement with the CDC, which involves determining the anti-infective and anti-inflammatory effectiveness of its Zofin formulation in experimental models for influenza infection.

The enterprise’s product portfolio comprises of an acellular biologic therapeutic dubbed Zofin, which has been developed to retain microRNAs which occur naturally. The formulation is undergoing a phase I/II clinical trial evaluating its effectiveness in treating the coronavirus. The enterprise also offers independent marketing, advertising and education services to medical and other regenerative, anti-aging and healthcare service providers.

As of July 2021, the FDA has approved the firm’s Investigational New Drug application for its Zofin formulation, which is indicated for the treatment of prolonged coronavirus symptoms. Given that many long-term effects of the coronavirus are unknown, the need to create new therapies that manage these prolonged symptoms is growing. This approval brings the company closer to achieving this effectively, which will help meet an unmet need and have a positive effect on the firm’s investments and growth.

Organicell Regenerative Medicine (OCEL), closed Tuesday's trading session at $0.059, off by 4.8387%, on 545,330 volume with 59 trades. The average volume for the last 3 months is 545,330 and the stock's 52-week low/high is $0.042/$0.63.

GreenBox POS (GBOX)

MarketClub Analysis and QualityStocks reported earlier on GreenBox POS (GBOX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GreenBox (NASDAQ: GBOX), an emerging fintech company leveraging proprietary blockchain security and token technology to build customized payment solutions, has appointed Jacqueline B. Reynolds as the company’s new chief marketing officer. In her new role, Reynolds will lead all marketing strategy, including the development of GreenBox’s brand positioning and communications plan. Reynolds served most recently as vice president of marketing for Sprouts Farmers Market, and she brings decades of experience with some of the world’s most coveted brands. She has built a reputation as a world-class global marketer, working with Coca-Cola, McDonalds, Verizon, Walmart, L’Oreal, Xbox, 7-Eleven and many other Fortune 500 companies.

As an executive in senior positions, Reynolds has managed award-winning programs with partners such as NFL, Super Bowl LIV, the Olympics, FIFA World Cup, Sony Pictures, Universal Music and others. “Jacqueline brings a bold vision, incredibly deep marketing experience and a data-driven approach to brand building,” said GreenBox CEO Fredi Nisan in the press release. “Her ability to shape the conversation, humanize the brand and establish GreenBox as a trusted solution will be critical in achieving our mission to build compliant, cutting-edge blockchain ledger tokenized payment solutions for the diverse, evolving and dynamic global market.”

To view the full press release, visit

About GreenBox POS

GreenBox is an emerging financial technology company leveraging proprietary blockchain security and token technology to build customized payment solutions. The company's applications enable an end-to-end suite of turnkey financial products, fraud detection and improving the efficiency of handling large-scale commercial processing volumes for its merchant clients. For more information about the company, please visit

GreenBox POS (GBOX), closed Tuesday's trading session at $6.36, off by 3.6364%, on 409,562 volume with 3,495 trades. The average volume for the last 3 months is 395,049 and the stock's 52-week low/high is $5.89/$20.78.

The QualityStocks Company Corner

AmpliTech Group Inc. (NASDAQ: AMPG)

The QualityStocks Daily Newsletter would like to spotlight AmpliTech Group Inc. (AMPG).

AmpliTech Group (NASDAQ: AMPG), a designer, developer and manufacturer of state-of-the-art, signal-processing components for satellite and 5G communications networks, defense, space and other commercial applications, has released its Q3 2021 financial results as well as results for its  first nine months of 2021. Third-quarter revenue totaled $1,056,595 for the quarter with the company contracting for $1.2 million in new orders for LNA technology in the fourth quarter, resulting in AmpliTech increasing its order backlog to a record $3.35 million as of Nov. 15, 2021, compared to a $2.45 million backlog in August 2021. The company also signed a lease for a 20,000-square-foot manufacturing and headquarters facility on Long Island, New York, with plans for the new facility to be in full operation by the first quarter in 2022. In addition, the company’s cash and equivalents and marketable securities reached $27.1 million by quarter end. “This is an extremely exciting time at AmpliTech as we are now well funded to position our industry leadership in radio frequency signal processing technologies in very large markets for satellite communications, 5G connectivity and quantum computing,” said AmpliTech CEO Fawad Maqbool in the press release. “At the core, our solutions and expertise enable our customers to move data with greater efficiency, reliability and at a lower cost. This value-add is particularly important given the enormous cost of the communications solutions in which our technologies are deployed. . . . Given the size and projected growth in each of our target markets, combined with the enhanced performance and ROI our solutions deliver, we believe AmpliTech is very well positioned for growth, particularly as the distraction of supply chain issues fades and our customers are able to focus on projects to support their long-term goals.” To view the full press release, visit

AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW) designs, develops and manufactures custom radio frequency (RF) components for the commercial, SATCOM, space and military markets. In addition to developing new products for the 5G/6G wireless ecosystem and infrastructure, the company has placed focus on the development of leading-edge solutions in quantum computing in support of U.S. efforts to reach the coveted position of quantum supremacy. The company maintains a commitment to R&D that allows it to remain at the forefront of emerging technologies. AmpliTech aims to use its advanced techniques and IP to provide tomorrow’s technology today, improving everyone’s quality of life.

AmpliTech was founded by Fawad Maqbool in 2002 to fill the need for affordable, high-quality, customized and state-of-the-art amplifiers and components. Headquartered in Bohemia, New York, the company currently has distributors and representatives available worldwide.

Product Portfolio

AmpliTech’s mission is to develop quality, state-of-the-art microwave amplifiers by leveraging its experience, proven technical expertise and superior design heritage. The company’s products cover a frequency range from 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz. Its current catalog includes:


Passive Components

All the company’s products come with a satisfaction guarantee, as the company is fully committed to providing only high-quality products free from manufacturing and material defects and guaranteed to perform according to applicable specifications.

Consulting Services

Leveraging more than 100 years of combined experience in microwave systems and component design ranging from active components to passive devices, AmpliTech also provides valuable consulting services and technical assistance to its customers.

With capabilities ranging from initial design to final manufacturing and delivery, the company’s team also offers project management services and advice on both technical aspects and how to handle business issues such as resource allocation, customer contact, budget restraints, time limits and more.

Other key benefits of AmpliTech consulting services that can give its customers a definitive edge include:

  • Timely technical assistance
  • Little or no learning curve
  • Less long-term costs associated with full-time employees with benefits and salaries
  • Availability when necessary
  • Customer support with schedules, project management and on the job training
  • Access to technology
  • Partnering for manufacturing and/or complete turn-key product solution
  • Personal guidance from concept to development
  • Custom designs for each application

Market Outlook

The global microwave devices market was valued at $7.44 billion in 2019 and is expected to grow at a CAGR of 3.23% and reach $9 billion by 2025 ( Governmental expenditures in the defense and space communications sectors are expected to expand the opportunities for growth within the industry.

AmpliTech continues to follow its strategy of identifying key elements in today’s technological revolution. It is leveraging its technical expertise and experience to align product portfolios and IP with innovation ( The company has plans to be a catalyst in the enhancement, development and distribution of breakthroughs in the following sizeable markets:

  • High Speed Terrestrial and Satellite Terminals (SATCOM, “Internet in the Sky”)
  • 5G/Wi-Fi6E and 6G wireless infrastructure (Cellular Base Stations, Small Cells, Private Wi-Fi Networks)
  • IoT (Internet of Things)
  • Cloud Farms, Big Data and MEC architecture
  • Quantum Supercomputers/Quantum Research
  • Deep Space Astronomy
  • Autonomous Self-Driving Vehicles
  • Telemedicine, AR/VR (Augmented and Virtual Reality)
  • Drones, UAVs (Unmanned Aerial Vehicles)
  • Cyber-security
  • Military/Defense ECM/EW

Management Team

Fawad Maqbool is the Founder, President, CEO and CTO of AmpliTech Group Inc. He has been in the microwave industry for over 30 years. Mr. Maqbool spent 14 years developing state-of-the-art amplifiers and components for MITEQ Inc., a leading microwave and communications equipment supplier. He founded AmpliComm in 2000, which was subsequently acquired by Aeroflex Inc. Mr. Maqbool has management and design experience, which has led to the development of microwave technology on a commercial and military level. He holds a B.S.E.E in Microwave Engineering and a B.S.E.E in Bio-Medical Engineering from CUNY and an M.S.E.E from the Polytechnic University of New York.

Louisa Sanfratello is the company’s CFO. She is a Certified Public Accountant (CPA) and has worked in various industries since 1998. During this time, she held roles as an accountant for charities and schools, consisting of the preparation of official financial documents and day-to-day financial management requirements. Ms. Sanfratello began her professional career in 1987 at Holtz, Rubinstein & Co., a public accounting firm. She gathered two years of experience there before gaining her CPA and taking on more challenging roles.

Brandon Worster is the company’s Director of Engineering. He joined AmpliTech at the end of 2019, bringing over 14 years of design and management experience. His specialty is Low Noise and Medium Power Amplifiers, but Mr. Worster also has vast experience with various systems, including RF/Microwave devices and systems. He holds a master’s degree in electrical engineering and is an adjunct professor at Farmingdale University in New York.

John P. Pastore is AmpliTech’s Director of Sales. He has worked in the microwave industry for more than 35 years, including time with some of the industry’s leading names. Mr. Pastore is a hands-on professional who has experience that spans over 20 years with progressive roles that blend technical, manufacturing, customer service and management expertise. He is an extremely valuable asset to the company as it moves forward due to his business savvy approach and deep industry knowledge. He has a B.S. in Business Management.

M. Syed handles Technical Sales and is the company’s Director of IT. He is an electrical engineer with more than 10 years of business experience. Since 2011, he has led Technical Sales for AmpliTech, and he recently became the President and CEO of his own company while also serving as Chief Technical Sales consultant for numerous other companies and groups in New York City. Mr. Syed has been in the IT industry for 25 years. He is a Computer Engineer by trade and a Certified Netware Engineer and Microsoft Certified Systems Engineer.

AmpliTech Group Inc. (AMPG), closed Tuesday's trading session at $4.16, up 0.240964%, on 414,962 volume with 1,518 trades. The average volume for the last 3 months is 414,264 and the stock's 52-week low/high is $1.782/$19.80.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM) and its subsidiary BayMedica are innovators in the field of rare cannabinoids, making them available for consumer access. InMed specializes in developing a proprietary biosynthesis system to manufacture pharmaceutical-grade cannabinoids that are otherwise too rare to be acquired in abundance. Through BayMedica, its recent acquisition, InMed also has capabilities in both yeast biosynthesis and chemical synthesis, catering to the large and growing health and wellness consumer markets. “The cannabis plant is made up of over 100 unique cannabinoids, many of which are only found in trace amounts,” reads a recent article. “With so many of these cannabinoids exhibiting the potential to fulfill several unmet medical needs industry-wide, InMed is working on the answer to mass production of rare and otherwise depleted cannabinoid opportunities. Unlike tetrahydrocannabinol (‘THC’) and cannabidiol (‘CBD’), which are found in excess within the cannabis plant, the goal for InMed and BayMedica is to use various manufacturing approaches to produce the amounts of rare cannabinoids necessary to fulfill the outstanding medical need in the industry.” To view the full article, visit:

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.


The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Tuesday's trading session at $1.4, up 4.4776%, on 107,607 volume with 339 trades. The average volume for the last 3 months is 107,108 and the stock's 52-week low/high is $1.2545/$6.42.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the Virtual Investor Roundtable Event, scheduled for Nov. 18, 2021. The CNSP overview, presented by CNS Pharmaceuticals CEO John Climaco and chief medical officer Sandra L. Silberman, MD, PhD. will begin at 9 a.m. ET. The presentation will be followed by a moderated roundtable discussion with time also included for questions and answers, which may be submitted by investors and interested parties during the live event. Questions may also be submitted for consideration before the presentation. A replay of the webcast presentation will be available following the event. To view the full presentation, visit To view the full press release, visit

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $1.275, up 12.8319%, on 3,463,407 volume with 6,269 trades. The average volume for the last 3 months is 3.441M and the stock's 52-week low/high is $1.10/$4.46.

Recent News

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Despite mounting pressure from increasing U.S. treasury yields, gold continued its rally this week. This comes as investors try to work with the expectation that major central banks around the globe will keep low interest rates in the short term. Gold futures in the United States rose by 0.5%, hitting $1825. 80/ounce in New York, while spot gold also carried on with its momentum from last week, rising by 0.4% to reach $1824.28/ounce. This is the highest price spot gold has occupied in two months. Before this, the price of gold futures in the U.S. was $1,810.10 per ounce while that of physical gold was at $1,810.28 per ounce. This ongoing bull run in the gold market has given companies such as Asia Broadband Inc. (OTC: AABB) a lot to smile about as they are delivering greater value to their investors and other stakeholders.

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Tuesday's trading session at $0.2229, up 1.6648%, on 54,919,232 volume with 4,425 trades. The average volume for the last 3 months is 54.898M and the stock's 52-week low/high is $0.0028/$0.659.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) offers an alternative solution to hydrogen distribution and storage issues through its proprietary on-site production of carbon-free ammonia (“NH3”) technology. The system is more energy efficient than conventional forms of NH3 production and does not emit CO2. “FuelPositive’s flagship modular and scalable carbon-free ammonia technology was developed by Dr. Ibrahim Dincer and his esteemed team at Ontario Technology University in Toronto. The platform will allow for in-situ production of NH3 sustainably. The process involves using only water, air and sustainable electricity,” reads a recent article. “Through its proprietary technology, FuelPositive is on track to create a viable option for replacing traditional fossil fuels while also becoming a leading provider on the expanding green ammonia market. The industry is expected to grow at a CAGR of 54.9% over the next decade.” To view the full article, visit

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Tuesday's trading session at $0.17, up 7.868%, on 726,328 volume with 157 trades. The average volume for the last 3 months is 726,328 and the stock's 52-week low/high is $0.03224/$0.326.

Recent News

StraightUp Resources Inc. (CSE: ST)

The QualityStocks Daily Newsletter would like to spotlight StraightUp Resources Inc. (CSE: ST).

  • Mineral property exploration company StraightUp Resources has pursued greater scale of its acquisitions and holdings in recent months, including properties in Canada, the United States, and Peru
  • StraightUp announced recently that it has upgraded its listing in the United States to the OTCQB Venture Market under the symbol STUPF to gain access to a larger investor base
  • StraightUp continues to be listed on the Canadian Securities Exchange under the symbol ST as well
  • The company’s flagship operations are in Ontario, where it has obtained options in several properties within the prolific Red Lake Mining Division’s greenstone belt

StraightUp Resources (CSE: ST) (OTCQB: STUPF), a company focused on acquiring select mining properties and a global scale of exploring for minerals, is expanding its access to investors by uplisting to the OTCQB Venture Market in the United States under the symbol STUPF.

StraightUp Resources Inc. (CSE: ST) is a public company engaged in the business of mineral exploration and the acquisition of mineral property assets in North America. The company’s flagship properties are located in the Red Lake Mining District of Ontario, Canada, renowned for over 30 million ounces of historic gold production. Other key projects extend into the neighboring Meen-Dempster Greenstone Belt of the Uchi Subprovince. The company’s management team is led by dedicated professionals, aiming to maximize shareholder value while employing modern exploration techniques and principles to achieve its goals.

The mission of StraightUp Resources is to maximize shareholder wealth through mineral discoveries at projects with robust potential, maintain long-lasting partnerships, and continue to focus on the acquisition, development and exploration of mineral resource properties in North America. The company’s objective is to continue to locate and develop economic, precious and base metal properties of merit.

The company’s 10,000-hectare (almost 25,000 acres) RLX Projects are contiguous to various Evolution Mining, Great Bear Resources, Pacton Gold and Dixie Gold properties. Its 2,000-hectare (just under 5,000 acres) Belanger Project is contiguous to Infinite Ore’s Fredart and Garnet/Arrow properties. StraightUp intends to conduct exploration on the RLX North, RLX South, Belanger and Ferdinand Gold properties located in the Red Lake District, a location touted as having one of the best metal-endowed greenstone belts in the world. The Bear Head Gold Project is located within the Meen-Dempster Greenstone Belt of the Uchi Subprovince, approximately 80 kilometers west of the Pickle Lake Gold Camp and 14 km northeast of the former gold mine, Golden Patricia. It amassed 620,000 ounces of gold at an average of 15.2 g/t Au from 1988-1997. The property is bordered by an Australian miner massive gold project. Known gold occurrences are already mapped on the Bear Head property, as are previous drill holes and results. Once the data is re-examined, an exploration budget and subsequent plans will be announced by the company.


Ontario’s Red Lake Mining District is one of Canada’s most prolific gold mining districts, renowned for its high-grade gold deposits. This is a mining-friendly, politically stable jurisdiction with a skilled labor force and infrastructure specifically built around meeting the needs of the mining industry.

RLX North & South Projects
At over 10,000 hectares, the RLX North and RLX South Projects represent a district-scale exploration opportunity. The RLX North and RLX South Projects are well positioned on-strike to the southeast of the district’s largest gold deposit (Red Lake Gold Mines – Evolution Mining). The project is adjacent to Great Bear Resources’ Sobel Project. Great Bear Resources is also in the process of evaluating the area for significant regional-scale structural controls and has proposed additional work on its neighboring project in the near term. These properties are highly accessible, with the southern boundary only eight kilometers from the paved highway into Red Lake, and can be accessed by forest service roads which traverse throughout the properties.

Belanger Project
Historic exploration work on the 2,000-hectare property has identified three significant surface exposures of gold, copper and silver. Early exploration work will focus on validating historic sampling results and following the occurrences along strike with a view to better understanding the nature and controls on mineralization. The property has excellent forest road access from the town of Ear Falls.

Ferdinand Gold Project
The Ferdinand property is situated within the southeastern extension of the Confederation-Uchi greenstone belt, one of the most metal-endowed greenstone belts in the world by square kilometer. It consists of 17 contiguous mining claims covering approximately 7,143 hectares (17,650 acres), located 13 kilometers northwest of the town of Slate Falls. Access is currently by logging roads, with forestry logging operations scheduled for expansion on the property. StraightUp recently completed a heliborne magnetic survey consisting of 1,994 line-km at 50m line spacings covering the entire property. The MAG survey was designed to provide geological and structural details of a 25km long southeast extension of the Confederation-Uchi greenstone belt along the Fry-Bamaji Deformation Zone.

Bear Head Gold Project
The Bear Head Gold Project comprises 31 mining claims totaling 1,944 hectares (4,800 acres) in the Meen-Dempster Greenstone Belt of the Uchi Subprovince, host to the Golden Patricia former gold mine, which produced 620,000 ounces of gold from 1988 to 1997. The Dorothy Main gold deposit owned by Ardiden lies only one kilometer from the Bear Head Gold Project. The Dorothy Main gold deposit holds noncompliant historical resources of 46,600 ounces of gold at 6.17 g/t Au. The company looks forward to adding the Bear Head Gold Project to its exploration efforts, with a work program to be conducted later in the fall of 2021.

Management Team

Mark Brezer is CEO, President, and Director of StraightUp Resources Inc. He is a successful businessman and holds a Geography/Geology degree from the University of Arizona. He has worked as a Project Manager and has overseen quality control, environmental monitoring and safety programs related to road construction. He has also held roles in media relations and marketing. He has been actively involved in the research and investment of junior mining companies for over 25 years. Time in the field and personal interest led him into extensive first aid training, and he is certified as a paramedic and firefighter.

Daniel Cruz is CFO and Director at StraightUp Resources. He is an experienced financial industry professional, having worked for 12 years as a senior investment advisor at Canadian broker-dealers, where he gained experience in equity research, asset management, investor relations, corporate finance and venture capital. He was one of the youngest Senior Investment Advisors at Canaccord Financial Inc. in 2010. He is also the co-founder and current director of Liquid Media Group Inc., a Nasdaq-listed issuer. During his tenure as CFO, he helped that company list on Nasdaq and raise over $20 million.

Matthew Coltura is a Director at StraightUp Resources. He has a Bachelor of Business Administration from Okanagan College, where he specialized in finance. He has worked in the finance industry for more than three years. Currently, Mr. Coltura is the CFO of Cayenne Capital Corp. He was also a director of PreveCeutical Medical Inc. from July 2016 to September 2019, a director of Sproutly Canada Inc. (formerly Stoneridge Exploration Corp.) from March 2015 to July 2018, and, since March 2018, has worked as a financial specialist at Quip Finance.

StraightUp Resources Inc. (CSE: STUPF), closed Tuesday's trading session at $0.162, even for the day. The average volume for the last 3 months is 100 and the stock's 52-week low/high is $0.1211/$0.27.

Recent News

Cannabis Strategic Ventures Inc. (OTC: NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures Inc. (NUGS).

With more than three-quarters of all American states now allowing some form of cannabis, the controversial plant is more accessible to the public than it has ever been. No longer is cannabis associated with drug addicts and criminals; normal folk are incorporating cannabis into their routines while remaining valuable members of society. However, many users fail to get the effects they seek from cannabis due to the plant’s unique nature. Unlike most drugs, cannabis affects people differently depending on a wide variety of factors. With entities such as Cannabis Strategic Ventures Inc. (OTC: NUGS) manufacturing a huge array of cannabis products, it helps to do your homework so that you choose exactly what will address your needs as a marijuana user.

Cannabis Strategic Ventures Inc. (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator. The company is based in Los Angeles, with a 6-acre cannabis farm in Northern California called NUGS Farm North. The company’s vision is to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration.

Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the City of Los Angeles and the State of California, and it is now working toward taking operational control of each license. The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with capacity to produce two to three pounds of premium exotic cannabis flower per light per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.

Brand Portfolio

The company owns multiple brands under the Cannabis Strategic Ventures umbrella. The firm’s NUGS brand provides operational and financial strategic partnerships and a range of essential services to emerging and existing cannabis consumer brands.

The NUGS Farm North brand operates as a six-and-a-half-acre cannabis cultivation property located in northern California. The company believes that the key to success in its business is consistent quality and reliable supply to fit growing consumer demand. Cannabis Strategic Ventures addressed these consumer needs by building NUGS Farm North. At NUGS Farm North, the company’s process is customized, and its product is consistent. Located in the heart of an agricultural mecca for globally distributed produce, NUGS Farm North finds power in its product, not in its size. Decades of agricultural experience and a dedication to consistency ensure quality cannabis.

MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. MDRN Tree will open its first Los Angeles location sometime in the fall of 2021. MDRN Tree will be the company’s factory retail store – a direct interface with the end-market community – where Cannabis Strategic Ventures plans on showcasing the cannabis flower produced at its NUGS Farm North cultivation site. This farm-to-sale model offers the potential to drive simultaneous gains in quality control and profitability.

Market Outlook

The demand for legal marijuana is expected to surge due to ongoing changes in U.S. state government policies toward cannabis. In addition, the number of indications for which medical marijuana is prescribed continues to increase steadily. These factors are expected to rapidly boost legal sales of cannabis products, opening new revenue channels for producers and retailers. Furthermore, an anticipated federal legalization of medical marijuana in the U.S. will only present more high growth opportunities for this market.

According to a report from Grand View Research, the global legal marijuana market was valued at $9.1 billion in 2020. Market size is forecast to grow at a compound annual growth rate of 26.7 percent from 2021 to 2028. That CAGR would put the market value at roughly $30 billion as soon as 2025.

According to the report, “One of the major factors fueling market growth is the expanding demand for legal marijuana owing to the growing number of legal cannabis countries. (Due) to recent legalizations in different countries, the use of medical marijuana for various ailments is gaining momentum worldwide. Patients suffering from chronic illnesses such as Parkinson’s, cancer, Alzheimer’s, and many neurological disorders are administered medical marijuana. The demand for cannabis oil is increasing rapidly, especially among countries with legalized medical marijuana.”

Management Team

Simon Yu is CEO, President, CFO and Secretary of Cannabis Strategic Ventures. He is also a co-founder, former COO and board member of Clubhouse Media Group Inc., a publicly traded social media company. Mr. Yu holds an MBA from the University of Southern California.

Cannabis Strategic Ventures Inc. (NUGS), closed Tuesday's trading session at $0.036, even for the day, on 6,785,963 volume with 133 trades. The average volume for the last 3 months is 6.53M and the stock's 52-week low/high is $0.035/$0.62.

Recent News Inc. (NASDAQ: LTRY)

The QualityStocks Daily Newsletter would like to spotlight Inc. (LTRY). (NASDAQ: LTRY, LTRYW), a leading technology company that is transforming how, where and when the lottery is played, has reported its Q3 2021 numbers for the period ended Sept. 30, 2021. Highlights of the report include third-quarter revenue reaching $32.2 million with a net income of $11.2 million; the company noted that the growth was driven by itsglobal affiliate marketing program. Gross profit for the period totaled  $20.3 million, an increase of $19.4 million from Q3 2020, with third-quarter 2021 net income reaching $11.2 million, compared to a net loss of $1.2 million for the same period last year. These results were achieved prior to the closing of the company’s business combination with Trident Acquisitions Corp., which was completed on Oct. 29, 2021. “We are proud of the strong revenue and profitability growth we achieved in the third quarter,” said cofounder and CEO Tony DiMatteo in the press release. “While we were working toward the completion of our business combination, we acted decisively to advance our plans for our global affiliate program and monetize one of our assets by leveraging a B2B partner relationship. The start of this program provided increased revenue in the third quarter and is an essential building block of our B2B2C strategy, which we expect will lead to an increased user base and additional revenue from those end users going forward. Additionally, the implementation of a dynamic pricing model and improvements to our app, such as push notifications, contributed to strong growth in gross profit per transaction compared to the prior year period. . . . Now that we have successfully completed our business combination, we are focused on utilizing the proceeds we realized from the transaction, along with our third-quarter profits, to accelerate our targeted user marketing campaigns, enter new markets, expand our product offerings, and execute strategic and synergistic acquisitions. With our low customer-acquisition costs, large addressable markets and leading brands, we look forward to realizing the profitable growth opportunities before us.” To view the full press release, visit Inc. (NASDAQ: LTRY) is a next generation platform where consumers can play the lottery online – in browser or via smartphone app. The platform offers users access to official lottery games sanctioned by their individual states and also provides lottery data to more than 400 digital publishers, including Google and Amazon Alexa. was founded in 2015, launching at the LAUNCH festival and soon turning into a leader in the industry. With headquarters in Austin, Texas, the company is dedicated to helping advance the lottery industry into the digital age and works closely with state regulatory bodies to achieve this goal.

The company recently entered into a definitive agreement for a business combination with special purpose acquisition company Trident Acquisitions Corp. (NASDAQ: TDAC) (“Trident”), which will result in becoming a publicly listed company. Once the transaction is complete, the combined company will be trademarked as, with its common stock to remain listed on Nasdaq under ticker symbol ‘LTRY’. Online Platform

The online platform works closely with state regulators, advancing the lottery into the digital age. With the online platform, the company offers enhanced regulatory capabilities by leveraging innovative blockchain technology and capturing the untapped market of digitally native players.

Players go online in a browser or through a mobile application to use the interface. The process includes:

  • Players Choose a Game: Players can play officially state sanctioned multi-state games and other games offered in the states in which they live. Players can also find winning numbers, jackpot totals, draw dates and more for hundreds of other lottery games around the world.
  • Players Pick Numbers: Players can play their lucky numbers or do a quick pick of randomized numbers in as simple as two taps. “Tap, Tap, Ticket!”
  • A Safe and Secure Way to Play: Purchases for up to 50 tickets can be made at one time through the online interface. handles everything after purchase, letting users know when they win.
  • Collect All Winnings: Consumers keep 100% of their winnings. All winnings stay in the balance for future ticket purchases, or a cashout can be requested. Company representatives contact winners who hit big jackpots, instructing them on the redemption process.

A Better Way to Play the Lottery has an innovative e-commerce platform that is using blockchain to maintain an accurate ledger. From 2016 to 2020, grew gross revenue at a CAGR of 363%, and it forecasts gross revenue equal to approximately $71 million in 2021, $279 million in 2022, and $571 million in 2023. is leveraging a successful playbook, with $398 billion in global lottery sales but only 6.7% online penetration. The large market opportunity is expected to shift to online transactions within the next decade.

The platform is currently available in 12 states across the United States, and the company plans to expand to 34 by the end of 2023. Global expansion is also on the horizon, with partnership plans in Turkey and Ukraine.

Key features that make the experience unique include:

  • All the Games Users Love – For consumers who live in applicable LIVE states, Powerball and Mega Millions are available right from the mobile application.
  • Convenience – makes playing the lottery on mobile devices easy. After setting up an account, users can begin playing in moments or set reminders to play when the jackpot is high.
  • Easy Cashouts – Users can cash out winnings straight to a bank account, safely and securely, with no commissions.

The company is also gamifying charitable giving, fundamentally changing how nonprofits engage with donors and raise funds. is a platform designed to offer charitable donation sweepstakes to incentivize donors to take action by offering large cash prizes and once-in-a-lifetime experiences.

Strong Advisory Board Presence is expected to continue to gain support, leaning on the experience of its advisory board and notable investors from the venture capital, gaming and entertainment industries. These include:

  • Jason Robins, CEO of DraftKings Inc. (NASDAQ: DKNG)
  • Ben Narasin, Venture Partner of NEA
  • Peter Diamandis, Chairman of XPRIZE Foundation
  • Matthew Le Merle, Co-Founder and Managing Partner of Fifth Era and Keiretsu Capital
  • Paraag Marathe, President of Enterprises and EVP of Football Operations for the San Francisco 49ers
  • Jamie Gold, The Poker Philanthropist

Management Team

Tony DiMatteo is the Co-Founder and Chief Executive Officer of He is a serial entrepreneur and highly sought-after industry speaker and thought leader. He has been featured in The Wall Street Journal, Forbes, VentureBeat, TechCrunch Inc. and more for his approach to entrepreneurship, the gaming industry and cryptocurrency.

Matt Clemenson is the Co-Founder and Chief Commercial Officer of He is responsible for the company’s strategy. Mr. Clemenson was steeped in corporate and enterprise engineering processes at Hotwire and Expedia before going on to be CEO at LesConcierges, the world’s largest concierge company, which merged into John Paul and sold to Accor Hotels. Clemenson and DiMatteo have been partners for more than 10 years.

Ryan Dickinson is the company’s President and Chief Operating Officer. He has a diverse background in business, technology, product, design and sales, which has aided him in producing many successful outcomes throughout his career. Notably, as Senior Vice President of a SaaS company, Mr. Dickinson produced profitability from a negative $1.4 million division within the first year by reinventing the product offerings, streamlining processes and establishing a go-to-market strategy. Additionally, he produced three record breaking revenue years in a row for AccuWeather, the world’s largest weather provider, by increasing every KPI for all flagship properties by no less than 5%.

Luc Vanhal is the company’s Chief Financial Officer. He has served in C-level executive roles since the 1990s, including a nine-year tenure for The Walt Disney Company (NYSE: DIS) from 1990 to 1999. From 2001 to 2004, he managed the development of the World of Warcraft massively multiplayer game, which, by the end of 2020, still had over five million active subscribers. As the CFO of, Mr. Vanhal leads the company’s global finance organization, with treasury responsibility, accounting, analysis and financial planning. Inc. (LTRY), closed Tuesday's trading session at $12.82, off by 1.9878%, on 1,967,609 volume with 11,900 trades. The average volume for the last 3 months is 1.951M and the stock's 52-week low/high is $12.25/$17.50.

Recent News


The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, has reported is financial and operations results for third quarter 2021, the period ending Sept. 30, 2021. Highlights of the report include revenue for the quarter reaching $8.3 million, an increase of 219% year-over-year, with revenue guidance for next quarter projected at $10.1 million, and third-quarter Sequire bookings of $8.9 million with fourth-quarter bookings totaling $12.5 million so far, a record for the company as Sequire has seen 12 consecutive quarters of revenue growth. In addition, the company launched IR Website Builder, SMS Communication platform and VIRA, an IR chatbot, and has seen 250 public companies or partners subscribe to Sequire. The report notes that SRAX currently holds approximately $29 million worth of marketable securities with a 78% gross margin as compared to 67% in the same period last year. “Our team continues to innovate on product, sales, and marketing, and this is translating into increased revenue,” said SRAX founder and CEO Christopher Miglino in the press release. “We will hit the high end of our 2021 guidance and are well positioned to close out 2021 strong, with an amazing 2022 on the horizon.” To see how VIRA(TM) works, visit To view the full press releases, visit and

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.


BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.


Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Tuesday's trading session at $5.17, off by 7.6786%, on 465,517 volume with 2,864 trades. The average volume for the last 3 months is 458,010 and the stock's 52-week low/high is $2.37/$7.29.

Recent News

Vivos Therapeutics Inc. (NASDAQ: VVOS)

The QualityStocks Daily Newsletter would like to spotlight Vivos Therapeutics Inc. (NASDAQ: VVOS).

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, has released is third-quarter 2021 financial report; the company also reported on operational highlights. The report noted that VVOS Q3 revenue increase more than 38% year over year, reaching $4.5 million for the third quarter of 2021 and $12.5 million for the nine months ended Sept. 30, 2021 as compared to $3.3 million and $9.8 million for the three and nine months for the same period last year. The company reported appliance sales of 2,996 total oral appliance arches, a 33% increase from the same period last year, with 8,648 total oral appliance arches, a 54% increase for the nine months ended Sept. 30, 2021, compared to the same period in 2020. Business highlights include more than 22,000 total patients have been treated with the Vivos System, compared to an estimated 13,000 for Q3 2020, with more than 1,350 dentists being trained in the use of the Vivos System and other related value-added services. In addition, the company was granted market clearance from the U.S. Food and Drug Administration for its mmRNA device designed to treat mild-to-moderate OSA, sleep-disordered breathing and snoring in adults. The company also opened an international training center in Denver and released positive results from an independent patient survey and separate clinical study related to its proprietary treatment. “The third quarter saw many positive developments for Vivos,” said Vivos chair and CEO R. Kirk Huntsman in the press release. “We recorded strong year-over-year growth, reflecting what we believe is growing recognition and adoption of our Vivos System as a treatment for mild-to-moderate sleep apnea. Our sales growth during the quarter, most notably in appliances, is beginning to reflect the impact of our previously announced strategic growth initiatives, including our expanded sales and marketing activities, featuring the broad introduction of our VivoScore diagnostic program. While we experienced a late summer decline in new VIP enrollments due in part to COVID-19, we are now generating revenue outside of our core of VIP enrollment revenue and appliance sales, including the value-added services we offer our VIPs and their patients as well as the beginnings of management revenue from our Medical Integration Division.” To view the full press release, visit

Headquartered in Denver, Colorado, Vivos Therapeutics Inc. (NASDAQ: VVOS) is an emerging global leader in the treatment of mild-to-moderate obstructive sleep apnea (OSA), a debilitating condition affecting nearly 1 billion people worldwide. The company utilizes proprietary, ground-breaking technology, a proven go-to-market strategy, and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep.

At the core of Vivos’ mission to rid the world of mild-to-moderate OSA is the Vivos System®, a revolutionary clinical breakthrough in the treatment of mild-to-moderate sleep apnea often caused by craniofacial anatomy development. The Vivos System® multidisciplinary treatment protocol involves collaboration between physicians, specially-trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health care providers.

In support of its growth strategy, Vivos has established contract manufacturing facilities in the U.S., Canada and Asia.

Market & Technology Overview

Craniofacial developmental deficiencies, such as underdeveloped upper and lower jaws, are among the leading causes of OSA. According to a 2019 analysis from researchers at the University of California, San Diego, an estimated 81 million adults in North and South America suffer from moderate to severe OSA. The United States has the highest amount of these patients, with approximately 54 million adults affected, according to the report.

Registered with the FDA as a Specification Developer, Vivos develops and markets a number of oral appliances. Its technology represents the first non-surgical, non-invasive and cost-effective treatment for the estimated hundreds of millions of people globally who suffer from mild-to-moderate OSA.

Vivos integrates its specially designed, customized appliances into a patient-specific, multi-disciplinary clinical protocol, giving trained dental and medical providers the tools and roadmap needed to address certain craniofacial conditions that studies have shown to be associated with sleep-disordered breathing—including mild-to-moderate OSA.

The system’s treatment protocol involves collaboration between physicians, specially trained dentists who have received advanced training in craniofacial sleep medicine, and additional health care providers. Vivos-trained clinicians can be found in almost every major city in the U.S. and in many countries throughout the world. The company’s oral appliances have shown to be effective in over 15,000 patients successfully treated worldwide by approximately 1,200 trained dentists.

A New Paradigm in Sleep Medicine

Vivos’ proprietary system poses the potential to be the biggest breakthrough in the treatment of mild-to-moderate OSA since CPAP.

The Vivos System has been specifically designed to promote the proper growth and development of the hard and soft tissues surrounding and comprising the oral cavity, nasal cavity, upper and lower jaws, and other tissues which together form and shape the upper airway. As these areas develop more fully using the Vivos System, a patient’s airway typically widens and expands, enabling them to breathe properly through their nose. With a more open and less obstructed airway, and easier nocturnal breathing, the symptoms of SDB tend to diminish over time, and patients often report they no longer suffer from the adverse effects of SDB or OSA.

Use of the Vivos System is variable and case dependent, but typically recommended to be worn daily for 12 to 16 hours starting in the early evening and continuing overnight. The total treatment time typically ranges from 12 to 24 months, with 18 months being the approximate mean treatment time.

Biomimetic Oral Appliance

Vivos Therapeutics believes that the Vivos System technology represents the first non-surgical, non-invasive and cost-effective treatment for people with mild-to-moderate OSA.

Combining technologies and protocols that can alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can significantly reduce symptoms and conditions associated with mild-to-moderate OSA.

The Vivos System treatment is typically less than $10,000 and is often reimbursable by medical insurance as an out-of-network benefit.

A potentially serious medical problem with an alternative treatment therapy available in the dental office.

Hard and soft tissues of the craniofacial complex can be non-surgically enhanced using the proprietary Vivos® System devices and clinical protocols.


R. Kirk Huntsman – CEO, Director
With experience in strategic development, technology acquisition and product planning, key talent recruitment, and target market prioritization, Huntsman brings a broad vision paired with leadership and strategic planning skills. He has significant start-up experience in a diverse range of market sectors, including medical devices, dental management, dental practice valuations and transitions, multi-location retail, financial and capital formation, consulting, outsourced services, imports and exports (China), medical services, and software and technology.

Dr. Dave Singh – Founder, Director
A doctor three times over in dental medicine, craniofacial development, and orthodontics, Dr. Singh was educated primarily in England and has lectured in North America, Europe, Asia, and Africa. The Global Summits Institute recently named Dr. Singh as one of the Top 100 Doctors in Dentistry.

Vivos Therapeutics Inc. (NASDAQ: VVOS), closed Tuesday's trading session at $3.26, off by 19.7044%, on 506,778 volume with 2,028 trades. The average volume for the last 3 months is 506,778 and the stock's 52-week low/high is $2.61/$14.41.

Recent News

Excellon Resources Inc. (NYSE American: EXN) (TSX: EXN) (FSE: E4X2)

The QualityStocks Daily Newsletter would like to spotlight Excellon Resources Inc. (NYSE American: EXN) (TSX: EXN) (FSE: E4X2).

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FRA: E4X2) has reported its financial results for the three- and nine-month periods ended Sept. 30, 2021. Highlights of the report include revenues of $9.2 million with gross profit of $1.8 million and total cash cost net of byproducts per silver ounce payable improved to $11.02. The company noted that all-in sustaining cost ("AISC") per silver ounce payable totaled $21.52, in part due to increased underground exploration at Platosa, with production cost of $281 per ton. Excellon also saw more than 21,000 tons mined and milled for the fifth quarter in a row, with sizeable stockpiles of ore and concentrate being processed and/or delivered in early October. EXN exploration expenditures increased for the quarter by 27% to $2.5 million, with increased drilling expenditures at Silver City, and the company ended the quarter with cash and marketable securities of $5 million. “Platosa continued to generate cash in Q3, which allowed us to realize our highest quarterly exploration expenditure since Q1 2013," said Excellon Resources president and CEO Brendan Cahill in the press release. “We continue to drill with two rigs at Silver City and aggressively follow up on the 817 Zone at Platosa, where we discovered a new, high-grade and vertical zone of mineralization beneath an area that was mined in 2017. We expect to release new results from 817 shortly. Revenues and costs have remained fairly stable over the past five quarters, though we have seen certain increases for electricity and labor, the latter due to labor law amendments in Mexico that took effect in Q3. Strong base metal prices and strengthening silver prices were beneficial in Q3 and have subsequently increased further. We also had ore in stockpile representing approximately 58,000 AgEq ounces at quarter-end, which will contribute to Q4 sales.” To view the full press release, visit

Excellon Resources Inc. (NYSE American: EXN) (TSX: EXN) (FSE: E4X2) (“Excellon” or the “Company”) is a silver and base metals producer with precious metal exploration and development projects in Mexico, Idaho and Germany. Since being founded in 1987, the Company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets.

Excellon is an active and influential member of the Mining Association of Canada (“MAC”). The Company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, the Company incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.

Precious Metals Growth Pipeline

The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration.

Maintaining and developing this pipeline presents the Company with enhanced opportunities in the expanding precious metals market, which was valued at $193.3 billion worldwide in 2020 ( This market is expected to increase at a compound annual growth rate (“CAGR”) of 9% from 2020 to 2027, resulting in an estimated $362.1 billion market size in 2027 ( Global market demand was calculated at 22,581.8 tons in 2020 and is expected to grow to 36,501.1 tons in 2027, achieving a CAGR of 3.5% (

Excellon reported strong results in terms of both production and average pricing at the end of Q4 2020, including:

  • Silver – 355,581 oz – $24.46
  • Lead – 2,223,465 lbs. – $0.87
  • Zinc – 2,452,728 lbs. – $1.21

Compared to Q4 2019, Excellon’s silver production increased by 37%, lead increased by 32% and zinc increased by 19% in Q4 2020 (

Platosa Mine – Silver, Lead, Zinc – Production, Development & Exploration

The Platosa Mine is located 5 km north of Bermejillo, Durango, Mexico, on a 14,000-hectare property. The mine commenced production in 2005 as an underground operation and is 100% owned and operated by Excellon. The Company is mining massive sulfide ores rich in silver, lead and zinc from a series flat-lying massive sulfide bodies (mantos) in a carbonate replacement deposit system. Historically, the mining method was a modified room and pillar method, which transitioned to cut-and-fill in recent years and overhand-cut-and-bench in 2020. The ore produced from the mine is transported 200 km south for processing at the Company’s 100% owned Miguel Auza mill.

Kilgore Project – Gold – Exploration & Resource Growth

The Kilgore Project is located in Clark County, situated in eastern Idaho in the United States. The project area is 100% owned and operated by Excellon. While still in the exploration and development phase, the primary target on the 13,627-acre site is an epithermal gold system. The property itself has historical mining that dates back to the 1930s, with modern mineral exploration beginning in the 1980s. The Kilgore Project displays characteristics similar to Kinross Gold’s Round Mountain Mine, which has produced more than 15 million ounces of gold since operations began in 1977.

Evolución Project – Mineral Processing, Resource Growth & Exploration

The Evolución Project is located in Miguel Auza, Zacatecas, Mexico, and hosts a large gold, silver, lead and zinc epithermal within a 45,000-hectare property that is 100% owned by Excellon. The site includes a processing facility with a mill and flotation circuit which processes ore from Excellon’s Platosa mine. The facility has a capacity of 800 tons per day, with a 650 ton-per-day ball mill in operation and a second 150 ton-per-day ball mill on standby. Excellon is looking at opportunities for toll milling, expansion and economic study of the mineral resource and grassroots exploration. Importantly, the project covers an unexplored 35-kilometer strike of the Fresnillo silver trend, the richest silver belt in the world.

Silver City Project – Exploration

Excellon holds an option to acquire the 16,400-hectare Silver City Project in Saxony, Germany. Initial drilling results in 2020 confirmed the presence of a high-grade, district-scale epithermal silver system over more than 12 kilometers of strike. The Company is now focused on defining wider zones of mineralization ( Silver City was mined from the 11th to late-19th century, until Germany moved off the silver standard in 1873. The deposits in the area were exceptionally high grade, with historical records indicating grades well in excess of 1,000 g/t silver.

Oakley Project – Exploration

The Oakley Project, located in Oakley, Idaho, is an exploration project with land holdings of approximately 7,000 acres. The project hosts gold-silver, epithermal hot spring-type mineralization at two targets: Blue Hill Creek and Cold Creek, and detachment-related gold-silver mineralization at Matrix Creek. The Company has granted Centerra (U.S.) Inc. an option to earn in to a 70% interest by, among other things, spending up to US$7 million in exploration expenditures on the project prior to May 2026.

Management Team

Brendan Cahill is the President & Chief Executive Officer of Excellon Resources Inc. He was previously Vice President Corporate Development of Pelangio Exploration Inc., a junior gold exploration company active in Ghana, West Africa. Mr. Cahill is a board member of the Mining Association of Canada, Group Eleven Resources Ltd., and Kore Mining Inc. He holds a law degree from the University of Western Ontario and an undergraduate degree from the University of Toronto.

Alfred Colas is the Company’s Chief Financial Officer. Most recently, he held the title of CFO of Arch Corp., a Toronto-based private-equity investment firm. Mr. Colas has over 18 years of experience in the mining industry. He is a sitting board member for a housing corporation affiliated with the University of Toronto and is a Chartered Professional Accountant. Mr. Colas completed a Bachelor of Commerce at the University of Toronto.

Paul Keller is Excellon’s Chief Operating Officer. He has over 30 years of industry experience in mining and mine development operations. He previously served as the Senior VP of Major Projects and COO of Trevali Mining. He has experience in building mines from greenfield through permitting, design and operation. Mr. Keller holds a Bachelor of Engineering – Mining from Laurentian University.

Ben Pullinger is the Senior Vice President Geology & Corporate Development for Excellon. Ben brings over 15 years of experience in advancing projects from early stage exploration through to production. Most recently, he was Vice President Exploration at Roxgold Inc., where he made a significant contribution toward growing the 55 Zone at Yaramoko Project into a producing mine. Mr. Pullinger serves on the board of Orford Mining. He is a Professional Geologist (Ontario) and holds an Honors Degree in Geology from the University of Johannesburg.

Excellon Resources Inc. (EXN), closed Tuesday's trading session at $1.44, off by 2.7027%, on 77,218 volume with 208 trades. The average volume for the last 3 months is 76,933 and the stock's 52-week low/high is $1.25/$3.90.

Recent News


The QualityStocks Daily Newsletter would like to spotlight LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF).

  • In preparation of the Lightning Network platform launch, Maynard Communications will provide a wide range of services such as search engine optimization, media relations consulting, digital media branding campaigns, project management, and multimedia services
  • The agreement between LQwD and Maynard allows the company to continue leveraging its position as a public company to enhance trust with its products and services
  • LQwD has purchased an additional CAD $4.5 million (USD $3.6 million) worth of Bitcoin, now holding a total of 133 Bitcoins at an individual cost of CAD $59,000 (USD $47,500) each

Financial technology company LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF) announced it has entered into an agreement with Maynard Communications Limited for various communications services in anticipation of the launch of its proprietary Lightning Network platform-as-a-service (“PaaS”). Dated November 4, the agreement will be in effect for a period of six months, with the opportunity to renew each month after that. The services that Maynard will provide to LQwD will include but are not limited to search engine optimization, media relations consulting, digital media branding campaigns, project management, and multimedia services ( Maynard manages a team in Hong Kong and has provided successful marketing for a broad range of companies listed on the TSX Venture Exchange.

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) is a financial technology company focused on creating enterprise-grade infrastructure to drive bitcoin adoption.

LQwD FinTech’s mission is to develop institutional-grade services that support the Lightning Network and drive improved functionality, transaction capability, user adoption and utility, and scaling of bitcoin. LQwD is also securing a substantial position in bitcoin as an operating asset and will use its holdings to establish nodes and payment channels on the Lightning Network.

The Lightning Network is a second-layer protocol, sitting above the bitcoin blockchain, intended to facilitate faster micro-transactions and lower fees on bitcoin transactions, thus allowing mass adoption of bitcoin.

LQwD expects the Lightning Network to eclipse the patchwork of legacy financial networks that are used to move value today. The company’s software will make migration from legacy networks onto the Lightning Network easy and seamless. By onboarding more financial service providers, LQwD intends to grow the value of the Lightning Network.

The company, formerly known as Interlapse Technologies Corp., is harnessing new payment rails built on top of the bitcoin blockchain that are capable of beyond visa-level transaction volumes and backed by bitcoin, the strongest and most well-known cryptocurrency. These new rails, enabled by the Bitcoin Lightning Network, open a vast opportunity and market segment for digital payments and financial services on a global scale. LQwD aims to leverage its position as a public company to enhance trust in its products and services, and leverage its shares as currency for acquisitions, roll-up and growth, as well as to attract and retain top industry talent.


The Lightning Network is a solution to massively scale the use of bitcoin for microtransactions globally, dramatically improving upon fees, as well as providing instant settlement times. The Lightning Network has experienced explosive growth and is expected to continue with the trend as usage increases. Well-known companies, such as Twitter and Square, have expressed their enthusiasm to incorporate Lightning Network into their platforms. The Lightning Network is scalable, global, open, inclusive, permissionless and decentralized. It is made up of nodes connected via payment channels, and enables off-chain, instantaneous and cheap payments at scale.

Upon launch of LQwD’s Lightning Network platform-as-a-service, users will be able to leverage the Lightning Network infrastructure to send payments instantly, securely and inexpensively anywhere in the world. Companies and service providers will be able to conduct Lightning Network transactions in bitcoin by integrating LQwD’s infrastructure with their business or web property. Connected businesses will be able to easily deploy, monitor and manage LQwD’s Lightning Network nodes with no or low-level technical knowledge required. The company fully expects Lightning Network to be a force for global change and to become the monetary exchange network of the future.

The Lightning Network, which is already built, functioning and growing, will advance bitcoin from a store-of-value to a global monetary network through payment utility. The company expects the Lightning Network will propel the growing number of active blockchain wallets to new heights, by increasing bitcoin’s scalability and lowering its fees for users. For coming generations, everything from wealth to experiences will be acquired and transacted virtually, and LQwD sees the Lightning Network as an enabling technology that can bring bitcoin to hundreds of millions of new users across the globe.

Market Outlook

Forbes in August 2021 noted that “private investors are funding companies that are building the infrastructure that will support future growth of crypto and digital assets,” and called public companies building cryptocurrency infrastructure “the hottest part of the crypto market.” While the first wave of investor interest in crypto firms was directed at companies catering to retail investors, investors have now shifted their attention to infrastructure builders, like LQwD FinTech. Forbes did not put an estimated value on the crypto infrastructure market but pointed out that large-scale adoption of cryptocurrencies will only happen when infrastructure is in place to support it. The larger digital payments market, of which crypto payments are a small fraction, is growing at more than 14 percent annually and is forecast to hit $154 billion by 2025.

Management Team

Shone Anstey is co-founder, chairman and CEO at LQwD FinTech. He has 20 years of experience in building complex technologies and has acted as technology lead for an industrial bitcoin mine and bitcoin mining pool. He is a Certified Cryptocurrency Investigator, and an advisor to the British Columbia Securities Commission. He is also co-founder of BIGG Digital Assets (OTCQX: BBKCF) and took that company public in 2017.

Barry MacNeil is CFO at LQwD FinTech. He is a member of the Chartered Professional Accountants of British Columbia and has more than 30 years of management and accounting experience with public companies and in private practice. His previous positions include director of both public companies and nonprofits, as well as Chief Financial Officer and Corporate Controller.

Albert Szmigielski is co-founder and CTO at LQwD FinTech. He was formerly the Head of Research and Chief Blockchain Engineer at Blockchain Intelligence Group and VP Research at CipherTrace. He holds a B.Sc. in Computing Science from Simon Fraser University, and a Master of Science in Digital Currencies and Blockchain Technologies from the University of Nicosia, Cyprus.

LQwD FinTech Corp. (LQWDF), closed Tuesday's trading session at $0.54, off by 2.5095%, on 43,931 volume with 42 trades. The average volume for the last 3 months is 43,931 and the stock's 52-week low/high is $0.20/$4.00.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Wednesday's trading